Dogwood Therapeutics: Halneuron Fase 2b CINP datos principales otoño 2026

El 8-K confirma que el ensayo Halneuron Fase 2b en dolor neuropático inducido por quimioterapia sigue según lo previsto con 164 pacientes inscritos y resultados principales previstos para el otoño de 2026. Por separado, la FDA aceptó la solicitud IND de SP16 para un estudio Fase 1b CIPPN que comenzará a reclutar a mediados de 2026.

Datos clave

Presentado: 14 may 2026, 12:50
Evento: Resultados principales
Dirección: Neutral
Empresa: DWTXDogwood Therapeutics
Activo: Halneuron
Fuente: SEC 8-K
Confianza: Con fuente
pacientes inscritos: 164

Extracto de la fuente

EX-99.1 2 dwtx-20260514xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy – - Announces Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Dogwood and its current and former shareholders - ALPHARETTA, Ga., May 14, 2026 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced financial results for the

SEC 8-K